Literature DB >> 23178578

Selectively reducing cytokine/chemokine expressing macrophages in injured nerves impairs the development of neuropathic pain.

Stefania Echeverry1, Yichen Wu, Ji Zhang.   

Abstract

It has been well documented that Wallerian degeneration following nerve injury is associated with inflammatory reaction. Such local inflammation contributes to the development of chronic neuropathic pain. Macrophages are one of the major players in the process of either or both degeneration/regeneration and hypersensitivity. To elucidate whether cellular and molecular changes involved in Wallerian degeneration are simultaneously involved in the induction and maintenance of neuropathic pain, and to identify which subpopulation of macrophages can be responsible for the chronic pain following nerve injury, we investigated the peripheral effects of an anti-inflammatory cytokine TGF-β1 in neuropathic pain. Rat sciatic nerves were partially ligated. Macrophages accumulated in injured sciatic nerves displayed heterogeneity with two distinctive functional phenotypes. While MAC1(+) macrophages were able to express IL-6 and MIP-1α, ED1(+) macrophages were always devoid of signals of inflammatory mediators. Intraneural injection of TGF-β1 resulted in delayed and attenuated neuropathic pain behaviour. In parallel, we observed that exposure of the nerve to TGF-β1 dramatically reduced the number of MAC1(+) macrophages. Consequently, the expression of IL-6 and MIP-1α decreased in the injured nerve. Very interestingly, local TGF-β1 treatment had no effect on the population of ED1(+) phagocytic macrophages. In addition to its effect on selective subsets of macrophages, TGF-β1 also reduced T-lymphocyte infiltration. Our results revealed the critical roles of cytokine/chemokine secreting MAC1(+) macrophages in the development of neuropathic pain, and highlighted the needs and benefits of targeting specific populations of macrophages in alleviating neuropathic pain without delaying nerve regeneration.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23178578     DOI: 10.1016/j.expneurol.2012.11.013

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  19 in total

1.  The role of G-protein receptor 84 in experimental neuropathic pain.

Authors:  Louise S C Nicol; John M Dawes; Federica La Russa; Athanasios Didangelos; Anna K Clark; Clive Gentry; John Grist; John B Davies; Marzia Malcangio; Stephen B McMahon
Journal:  J Neurosci       Date:  2015-06-10       Impact factor: 6.167

2.  Assessment of Motor Function in Peripheral Nerve Injury and Recovery.

Authors:  Albin John; Stephen Rossettie; John Rafael; Cameron Cox; Ivica Ducic; Brendan Mackay
Journal:  Orthop Rev (Pavia)       Date:  2022-09-13

Review 3.  Role of Transforming Growth Factor Beta in Peripheral Nerve Regeneration: Cellular and Molecular Mechanisms.

Authors:  Zhiqian Ye; Junbin Wei; Chaoning Zhan; Jin Hou
Journal:  Front Neurosci       Date:  2022-06-13       Impact factor: 5.152

4.  Sexually Dimorphic Immune and Neuroimmune Changes Following Peripheral Nerve Injury in Mice: Novel Insights for Gender Medicine.

Authors:  Valentina Vacca; Sara Marinelli; Federica De Angelis; Daniela F Angelini; Eleonora Piras; Luca Battistini; Flaminia Pavone; Roberto Coccurello
Journal:  Int J Mol Sci       Date:  2021-04-22       Impact factor: 5.923

5.  Treatment-Induced Neuropathy in Diabetes (TIND)-Developing a Disease Model in Type 1 Diabetic Rats.

Authors:  Petra Baum; Severin Koj; Nora Klöting; Matthias Blüher; Joseph Classen; Sabine Paeschke; Martin Gericke; Klaus V Toyka; Marcin Nowicki; Joanna Kosacka
Journal:  Int J Mol Sci       Date:  2021-02-04       Impact factor: 5.923

6.  Immunotherapy targeting cytokines in neuropathic pain.

Authors:  Justin G Lees; Samuel S Duffy; Gila Moalem-Taylor
Journal:  Front Pharmacol       Date:  2013-11-22       Impact factor: 5.810

7.  A new animal model of spontaneous autoimmune peripheral polyneuropathy: implications for Guillain-Barré syndrome.

Authors:  Mu Yang; Anthony Rainone; Xiang Qun Shi; Sylvie Fournier; Ji Zhang
Journal:  Acta Neuropathol Commun       Date:  2014-01-08       Impact factor: 7.801

8.  Evaluation of postoperative outcomes in patients following multi-level surgical reconstructions with the use Avive soft tissue membrane on nerve after traumatic injury of the upper extremity and lower extremity.

Authors:  Cameron T Cox; Joash R Suryavanshi; Bradley O Osemwengie; Sterling Rosqvist; Matthew Blue; Desirae McKee; Brendan J MacKay
Journal:  SAGE Open Med       Date:  2021-06-06

9.  Use of Integrated Optical Clearing and 2-Photon Imaging to Investigate Sex Differences in Neuroimmune Interactions After Peripheral Nerve Injury.

Authors:  Thomas A Szabo-Pardi; Umar M Syed; Zachary W Castillo; Michael D Burton
Journal:  Front Cell Dev Biol       Date:  2021-02-18

10.  ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response.

Authors:  Maarten Swartjes; Monique van Velzen; Marieke Niesters; Leon Aarts; Michael Brines; Ann Dunne; Anthony Cerami; Albert Dahan
Journal:  Mol Pain       Date:  2014-02-16       Impact factor: 3.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.